2015-04-30

[DIV28SUPER] Statement from APA in response to April 30, 2015 New York Times article

April 30, 2015

APA Public and Member Communications

 

Statement from APA in response to April 30, 2015 New York Times article

 

Members have contacted the APA Central Office expressing concerns about this morning's New York Times article which recirculated allegations about APA support for the CIA's torture program.  We understand those concerns.  APA senior governance and staff take the allegations of support for torture and the public misunderstanding they have created very seriously.  

When James Risen first made his allegations last October we released a statement refuting them(http://www.apa.org/news/press/releases/2014/11/risen-allegations.aspx). However, due to the seriousness of the allegations we believed that they required an independent and definitive review.  As you know, outside attorney David Hoffman of the law firm Sidley Austin was asked to conduct such a review.  Mr. Hoffman has broad experience in conducting independent reviews and an unchallenged reputation for independence and integrity.  His work on the review is ongoing.  

Mr. Hoffman's review is fully independent and it is important that it be perceived as such by the public.  Toward that end, and while the review is on-going, APA is not making any comment on the merit of the allegations.  Mr. Hoffman has full and unfettered access to the people and documents he deems necessary for the review – to the extent APA can control such access.  His report will determine the facts.  While we are hopeful that the report will clear APA's name (especially since the allegations are so antithetical to psychology's mission and APA's actual work) we believe that it is important that Mr. Hoffman be given as much time as he needs to do a thorough review.    Regardless of the outcome, we believe the independent review is critical to the Association being able to move forward.

We tentatively expect the review to be completed later this spring or early this summer but the final completion schedule will be determined by Mr. Hoffman.  Once it is completed and the report received and reviewed by the APA Board of Directors (with input from the APA Council of Representatives) it will be made public, in its entirety, along with any initial responsive actions that APA determines are needed. The Council will also have a second opportunity to review the report and take additional actions during its August meeting.

-2-

When the report is released, we will undertake a proactivecommunications program to inform members and the general public of the report findings.  That outreach will include contact with national and international media, social media outreach and a same-day communications to all APA members.

In terms of what APA has done today, we have shared a response statement with media and have also posted a response to Facebook and Twitter.   More information is also available on the APA website. If you are interested in a full chronology of APA's action and policies concerning national security interrogations see:

http://www.apa.org/news/press/statements/interrogations.aspx

 


2015-04-24

[DIV28_ANNOUNCEMENT] UAMS postdoctoral position

POST-DOCTORAL POSITIONS IN DRUG ABUSE PHARMACOLOGY AND TREATMENT AT THE UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES

 

We are currently seeking Post-Doctoral Fellows with strong technical skills in preclinical models of drug abuse, and broader interest in the science of drug addiction, for positions within two NIH/NIDA R01 projects "Antibody Gene Therapy for Methamphetamine Abuse," (Eric Peterson PI) and "Pharmacology and Therapy for MDPV and alpha-PVP Like Drugs of Abuse" (Michael Owens, PI) within the Department of Pharmacology and Toxicology, and our NIH/NIDA T32 "Translational Training in Addiction" (Clint Kilts, PI) at the University of Arkansas for Medical Sciences in Little Rock. The selected candidates will become members of our interdisciplinary collaborating laboratories with ongoing, funded projects related to development of novel pharmacotherapeutics for psychostimulant addiction and toxicities. The T32 fellowship position is funded for two years, while the R01-supported positions could be funded for up to 3 years.

 

Our laboratories within the Department of Pharmacology and Toxicology are especially focused on (1) using behavioral pharmacology assays to understand the abuse-related effects of drugs (i.e., intravenous self-administration, drug discrimination) as well as their persistent effects on physiology and behavior (i.e., biotelemetry of locomotor activity, thermoregulation and cardiovascular effects, as well as assays relevant to psychosis, learning and memory), (2) designing novel antibody-based medications against psychostimulants, which slow entry of these drugs into the brain by binding them in the blood. A synthesis of these two areas of research allows us to test the therapeutic potential of these novel pharmacotherapies using a range of in vitro and in vivo models, and provides a fertile interdisciplinary training environment for fellows. Our drug abuse research group is part of an extensive network of addiction science efforts across several research Centers and Colleges at UAMS, including analytical chemistry and product surveillance at the Arkansas Department of Health, clinical scientists at the Psychiatric Research Institute and the Arkansas Children's Hospital, community-based research programs through the Division of Health Services Research, and our own pharmacology laboratories within the College of Medicine. Successful candidates will have strong communication skills and clear technical expertise, with a focus on either in vitro (e.g., expression analysis, Western blots, and receptor binding assays) or in vivo (e.g., operant behavior, locomotor activity) models. Demonstrated ability to apply more advanced tools (e.g., pharmacokinetic modeling, HPLC separation and detection in biological samples), and the ability to integrate in vivo and in vitro measures will be an advantage. The ability to publish research findings is important for these training positions. Candidates will have completed an MD or Ph.D. or equivalent degree in a relevant discipline (e.g., biomedical engineering, pharmacology, neuroscience, biological psychology, etc.). The University of Arkansas for Medical Sciences is an Equal Opportunity / Affirmative Action Employer. Minorities and women are strongly encouraged to apply. US Citizenship or Permanent Resident status (green card) is required. Applications will be considered until the position is filled. Please e-mail an up-to-date CV, the names of 3 references, and a one-page letter of interest describing your potential fit for the position to Associate Professor of Pharmacology and Toxicology Dr. William Fantegrossi (WEFantegrossi@uams.edu).

 

For more information contact:

    William Fantegrossi, Ph.D.

    Email: WEFantegrossi@uams.edu


               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are
confidential and are intended solely for the addressee. The information
may also be legally privileged. This transmission is sent in trust, for
the sole purpose of delivery to the intended recipient. If you have
received this transmission in error, any use, reproduction or
dissemination of this transmission is strictly prohibited. If you are
not the intended recipient, please immediately notify the sender by
reply e-mail or at (859) 257-5383 and delete this message and its
attachments, if any.

2015-04-16

[DIV28SUPER] Fwd: [NDEWS-NETWORK] NDEWS Network: E-Cigarettes, New Findings from the 2014 National Youth Tobacco Survey



Sent from my iPhone

Begin forwarded message:

From: "Eleanor E. Artigiani" <eartigia@UMD.EDU>
Date: April 16, 2015 at 5:41:28 PM EDT
To: NDEWS-NETWORK@LISTSERV.UMD.EDU
Subject: [NDEWS-NETWORK] NDEWS Network: E-Cigarettes, New Findings from the 2014 National Youth Tobacco Survey
Reply-To: "Eleanor E. Artigiani" <eartigia@UMD.EDU>

The NDEWS Coordinating Center thought you would be interested to know that CDC and FDA released results from the 2014 National Youth Tobacco Survey (YTS) this afternoon. The results discussed in the press release "show that current e-cigarette use (use on at least 1 day in the past 30 days) among high school students increased from 4.5 percent in 2013 to 13.4 percent in 2014, rising from approximately 660,000 to 2 million students. Among middle school students, current e-cigarette use more than tripled from 1.1 percent in 2013 to 3.9 percent in 2014—an increase from approximately 120,000 to 450,000 students. This is the first time since the survey started collecting data on e-cigarettes in 2011 that current e-cigarette use has surpassed current use of every other tobacco product overall, including conventional cigarettes. (CDC, 4/16/15)"

The CDC press release has been picked up by numerous news outlets. Here are links to the press release, the MMWR article, and stories put out today by the New York Times and Reuters.

 

CDC Press Release: http://www.cdc.gov/media/releases/2015/p0416-e-cigarette-use.html

MMWR: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6414a3.htm?s_cid=mm6414a3_w

New York Times: http://www.nytimes.com/2015/04/17/health/use-of-e-cigarettes-rises-sharply-among-teenagers-report-says.html

Reuters: http://news.yahoo.com/e-cigarette-soared-smoking-rate-fell-among-u-170831445--finance.html;_ylt=A0LEVjr7IzBV14wA8IgnnIlQ;_ylu=X3oDMTEzaXFocm5pBGNvbG8DYmYxBHBvcwMxBHZ0aWQDWUhTMDAzXzEEc2VjA3Nj

 

Erin Artigiani

Deputy Director for Policy

Center for Substance Abuse Research (CESAR)

4321 Hartwick Rd, Ste 501

College Park, MD 20740

301-405-9794

410-746-0793 (cell)

eartigia@umd.edu

www.cesar.umd.edu

www.mdcsl.org

 



You have received this email message as a member of the NDEWS Network discussion list. You can delete yourself from the list by sending an email to listserv@listserv.umd.edu with "unsubscribe ndews-network" (without the quotes) in the body of the email.
To change your settings, look through the archives, or subscribe a new subscriber, go to www.listserv.umd.edu/archives/ndews-network.html.
NDEWS is funded under NIDA Cooperative Agreement DA038360, awarded to the Center for Substance Abuse Research (CESAR) at the University of Maryland, College Park. Opinions expressed by participants on the NDEWS Network electronic mailing list may not represent those of CESAR, UMD, or NIDA. CESAR, UMD, and NIDA cannot attest to the accuracy of the statements made by participants of the NDEWS Network electronic mailing list.

2015-04-11

[DIV28SUPER] Removal

Please remove me from the list

Thanks josh crick

Sent from my Windows Phone

Re: [DIV28SUPER] Marijuana

Krista,


I saw your report from an television news station (YouTube) and found it fascinating about the results coming in. I also enjoyed the article from NYT that Dan sent. I know as well as you know, that A LOT of people take psychiatric medications every day, what are the effects of taking psychiatric medication (i.e, antidepressants, anti-anxiety, etc) on the brain in comparison to how marijuana effects the brain? I know the confounds of each since some people still smoke tobacco and mix marijuana with alcohol and some mix all three (alcohol, marijuana, psychiatric medications). Since our society and sometimes say it is "better living through chemistry", I wonder when you compare the taking of psychiatric medication or lets just narrow it down to antidepressants and anti-anxiety medication, which has the worse effects on the brain and behavior? Marijuana or psych meds from those categories I listed?


I ask this because adolescents, adults, college students will ask this. Adolescents will say that it doesn't have the man made "tar" and "nicotine" that marijuana has and therefore marijuana is "healthier".


Some random thoughts as the wave of legalization hits us...

Bill Hosmer, PhD


-----------------------------------------

From: "Krista Lisdahl"
To: mr.sanders@charter.net
Cc: DIV28SUPER@lists.apa.org
Sent: Sat, 11 Apr 2015 13:51:42 -0500
Subject: Re: [DIV28SUPER] Marijuana

There were too many articles for the listserv- but I wanted to share the two websites to the whole group. (Bill, let me know if you did not receive the articles.)

Best,
Krista


On Sat, Apr 11, 2015 at 1:48 PM, Krista Lisdahl <krista.medina@gmail.com> wrote:
Hello Bill,

My name is Krista Lisdahl, and studying the neurocognitive effects of Marijuana is my specialty area. I also consult on a lot of policy work (e.g., I serve on the DHHS cannabis board on WI, who is preparing a report on MJ policy considerations- e.g., cannabinoid science- esp medicinal uses, prohibition vs. decriminalization vs. legalization). I'm attaching 2 review articles,a couple articles re: medicinal research, and a few articles focused on MJ policy. There are tons of resources, but this will get you started. I'd also recommend you look the Marijuana Science Forum (http://marijuanascienceforum.org/) which tracks some of this research. The University of Washington also has a good site: http://learnaboutmarijuanawa.org/.

Best,

Krista

On Sat, Apr 11, 2015 at 1:24 PM, Bill Hosmer, PhD <mr.sanders@charter.net> wrote:

QUESTION:


1-I am looking for either or both excellent resources (e.g., texts, journal articles, etc.) on marijuana (good effects, bad, etc.). Since its legalization in some states and pushing quickly forward in others, I would like to know the pros/cons of using this. I primarily work with kids (3-22 y/o) and families and would like to know the scientific facts about this


Thanks in advance,

Bill Hosmer, PhD


-----------------------------------------

From: "Ronald Wood"
To: DIV28SUPER@LISTS.APA.ORG
Cc:
Sent: Sat, 11 Apr 2015 04:13:56 -0400
Subject: [DIV28SUPER] NYTimes: Milder Warning Opposed for Swedish Tobacco Item

http://www.nytimes.com/2015/04/11/science/milder-warning-opposed-for-swedish-tobacco-item.html?smid=nytcore-ipad-share&smprod=nytcore-ipad

Swedish Match argues its product, Snus — moist ground tobacco in a sachet to be tucked between the lip and the gum — is far less harmful than cigarettes.


Sent from my iPad
___________________ div28SUPER@lists.apa.org _____________________
Div28m members may post here subscribers corner: http://lists.apa.org

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 join our network




--
Krista M. Lisdahl, Ph.D.
(formerly Krista Lisdahl Medina)
krista.medina@gmail.com; medinak@uwm.edu 
Associate Professor
University of Wisconsin-Milwaukee
Psychology Department, Garland Hall Rm 224
2441 East Hartford Ave
Milwaukee, WI 53211 

 





--
Krista M. Lisdahl, Ph.D.
(formerly Krista Lisdahl Medina)
krista.medina@gmail.com; medinak@uwm.edu 
Associate Professor
University of Wisconsin-Milwaukee
Psychology Department, Garland Hall Rm 224
2441 East Hartford Ave
Milwaukee, WI 53211 

 


Re: [DIV28SUPER] Marijuana

There were too many articles for the listserv- but I wanted to share the two websites to the whole group. (Bill, let me know if you did not receive the articles.)

Best,
Krista


On Sat, Apr 11, 2015 at 1:48 PM, Krista Lisdahl <krista.medina@gmail.com> wrote:
Hello Bill,

My name is Krista Lisdahl, and studying the neurocognitive effects of Marijuana is my specialty area. I also consult on a lot of policy work (e.g., I serve on the DHHS cannabis board on WI, who is preparing a report on MJ policy considerations- e.g., cannabinoid science- esp medicinal uses, prohibition vs. decriminalization vs. legalization). I'm attaching 2 review articles,a couple articles re: medicinal research, and a few articles focused on MJ policy. There are tons of resources, but this will get you started. I'd also recommend you look the Marijuana Science Forum (http://marijuanascienceforum.org/) which tracks some of this research. The University of Washington also has a good site: http://learnaboutmarijuanawa.org/.

Best,

Krista

On Sat, Apr 11, 2015 at 1:24 PM, Bill Hosmer, PhD <mr.sanders@charter.net> wrote:

QUESTION:


1-I am looking for either or both excellent resources (e.g., texts, journal articles, etc.) on marijuana (good effects, bad, etc.). Since its legalization in some states and pushing quickly forward in others, I would like to know the pros/cons of using this. I primarily work with kids (3-22 y/o) and families and would like to know the scientific facts about this


Thanks in advance,

Bill Hosmer, PhD


-----------------------------------------

From: "Ronald Wood"
To: DIV28SUPER@LISTS.APA.ORG
Cc:
Sent: Sat, 11 Apr 2015 04:13:56 -0400
Subject: [DIV28SUPER] NYTimes: Milder Warning Opposed for Swedish Tobacco Item

http://www.nytimes.com/2015/04/11/science/milder-warning-opposed-for-swedish-tobacco-item.html?smid=nytcore-ipad-share&smprod=nytcore-ipad

Swedish Match argues its product, Snus — moist ground tobacco in a sachet to be tucked between the lip and the gum — is far less harmful than cigarettes.


Sent from my iPad
___________________ div28SUPER@lists.apa.org _____________________
Div28m members may post here subscribers corner: http://lists.apa.org

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 join our network




--
Krista M. Lisdahl, Ph.D.
(formerly Krista Lisdahl Medina)
krista.medina@gmail.com; medinak@uwm.edu 
Associate Professor
University of Wisconsin-Milwaukee
Psychology Department, Garland Hall Rm 224
2441 East Hartford Ave
Milwaukee, WI 53211 

 





--
Krista M. Lisdahl, Ph.D.
(formerly Krista Lisdahl Medina)
krista.medina@gmail.com; medinak@uwm.edu 
Associate Professor
University of Wisconsin-Milwaukee
Psychology Department, Garland Hall Rm 224
2441 East Hartford Ave
Milwaukee, WI 53211 

 


_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 join our network

Re: [DIV28SUPER] Marijuana

QUESTION:


1-I am looking for either or both excellent resources (e.g., texts, journal articles, etc.) on marijuana (good effects, bad, etc.). Since its legalization in some states and pushing quickly forward in others, I would like to know the pros/cons of using this. I primarily work with kids (3-22 y/o) and families and would like to know the scientific facts about this


Thanks in advance,

Bill Hosmer, PhD


-----------------------------------------

From: "Ronald Wood"
To: DIV28SUPER@LISTS.APA.ORG
Cc:
Sent: Sat, 11 Apr 2015 04:13:56 -0400
Subject: [DIV28SUPER] NYTimes: Milder Warning Opposed for Swedish Tobacco Item

http://www.nytimes.com/2015/04/11/science/milder-warning-opposed-for-swedish-tobacco-item.html?smid=nytcore-ipad-share&smprod=nytcore-ipad

Swedish Match argues its product, Snus — moist ground tobacco in a sachet to be tucked between the lip and the gum — is far less harmful than cigarettes.


Sent from my iPad
___________________ div28SUPER@lists.apa.org _____________________
Div28m members may post here subscribers corner: http://lists.apa.org

[DIV28SUPER] NYTimes: Milder Warning Opposed for Swedish Tobacco Item

http://www.nytimes.com/2015/04/11/science/milder-warning-opposed-for-swedish-tobacco-item.html?smid=nytcore-ipad-share&smprod=nytcore-ipad

Swedish Match argues its product, Snus — moist ground tobacco in a sachet to be tucked between the lip and the gum — is far less harmful than cigarettes.


Sent from my iPad
___________________ div28SUPER@lists.apa.org _____________________
Div28m members may post here subscribers corner: http://lists.apa.org

2015-04-10

[DIV28SUPER] Very. Very Brief Survey on Animal Research for RSA Members

Hello,

 

The RSA Animal Research and Ethics Committee has prepared a brief survey to gauge our membership’s awareness and attitudes regarding the use of animals in alcohol research.  This survey only has a few questions and should take no more than 2-3 minutes to complete.  Your responses are very important and will be completely anonymous.  The survey can be found here:

 

https://yalesurvey.qualtrics.com/SE/?SID=SV_01hvNPay8jiQ0tv

 

If you are an RSA member and have not yet completed the survey, we would really appreciate it if you would navigate to the link below and complete the survey.

 

*** Please only complete the survey if you are a current member of RSA ***

 

Thank you, in advance, for taking the time to complete this survey.

 

Best,

 

Rob Leeman

 

 

 

Robert F. Leeman, Ph.D.
Assistant Professor, Department of Psychiatry

Yale School of Medicine

Research Scientist,

VA New England (VISN 1) Mental Illness Research, Education and Clinical Center (MIRECC)

CMHC, Room S-200
34 Park Street
New Haven, CT  06519
TEL: (203)974-7373
FAX: (203)974-7606
robert.leeman@yale.edu

http://psychiatry.yale.edu/people/robert_leeman.profile

------------------------------

The information contained in this message may be privileged and confidential. if you are NOT the intended recipient, please notify the sender immediately with a copy to hipaa.security@yale.edu and destroy this message.

 

Please be aware that email communication can be intercepted in transmission or misdirected. Your use of email to communicate protected health information to us indicates that you acknowledge and accept the possible risks associated with such communication. Please consider communicating any sensitive information by telephone, fax or mail. If you do not wish to have your information sent by email, please contact the sender immediately.

 

2015-04-07

[DIV28SUPER] ADHD Research Award Program 2015 - Applications Now Available

 

ADHD Research Award Program 2015 – Applications Now Available

 

CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) is pleased to announce the 2015 Young Scientist Research Awards, a program to recognize young researchers making contributions to the understanding of ADHD. 

 

Two awards will each include an unrestricted cash prize of $1,000, recognition at CHADD’s 27th Annual International Conference in New Orleans, conference travel, registration and expense allowance, a one-year professional membership to CHADD, and recognition in CHADD's Attention magazine and on CHADD’s website.  Applicants must be in the process of completing a doctoral degree or have completed one within the last three years with the doctoral degree awarded no earlier than January 2012.

 

Research may address any area relevant to ADHD including, but not limited to: biological/genetic underpinnings of the disorder; treatment efficacy; impact on the individual or family; school or workplace accommodations; social stigma and discrimination; public health; and epidemiology.

 

The awards are currently being supported by a number of individual donations.

 

Deadline for applications is May 15, 2015.  For an application or for more information, go to www.chadd.org/youngscientist or send an email to youngscientist@chadd.org.

 

Thank you very much.

 

Sincerely,

 

Ms. Zuali Malsawma, MLS

YSRA Program Coordinator/Librarian

National Resource Center on ADHD: A Program of CHADD

4601 Presidents Drive, Suite 300

Lanham, MD 20706

240-487-2330 (direct)

301-306-7070 x130 (main)

www.help4adhd.org / www.chadd.org

 

 

2015-04-06

[DIV28SUPER] NIDA Neuroscience Update April 6, 2015

Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01)  PAR-15-120

 

Next due date: June 30, 2015

 

The goals of this initiative are to identify gene variants of traits associated with addiction and substance abuse in selectively bred, and outbred  non-human animal models using methodologies of Next Gen-Sequencing, mapping, and genotyping.

This FOA will replace PAR-14-010 "Identification of Gene Variants for Addiction Related Traits by Next-Gen Sequencing in Model Organisms Selectively Bred for Addiction Traits (UH2/UH3)".

See more at: http://grants.nih.gov/grants/guide/pa-files/PAR-15-120.html#sthash.bBPhto89.dpuf

----------

BRAIN Initiative NSF Funding Opportunity - Cracking the Olfactory Code   NSF 15-547

Preliminary Proposal Due Date(s) (required) (due by 5 p.m. proposer's local time):  May 01, 2015

Full Proposal Deadline(s) (due by 5 p.m. proposer's local time): July 31, 2015

 

NSF is launching a special activity as part of NSF's engagement in President Obama's BRAIN Initiative.  A link to this activity, an Ideas Lab focused on "Cracking the Olfactory Code," can be found here: http://www.nsf.gov/pubs/2015/nsf15547/nsf15547.htm?org=NSF. The aim of this Ideas Lab to facilitate the generation and execution of innovative research projects aimed at understanding the nature of olfactory processing and sensory representations in the brain in general.  The aspiration is that bringing together researchers from diverse scientific backgrounds will engender fresh thinking and innovative approaches that will transform our understanding of olfactory processing in behavioral contexts while spawning new opportunities to elucidate the general nature of sensory representations in the brain.

----------

Notice of the National Institute on Drug Abuse (NIDA) Participation in PAR-15-070 "Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)" (NOT-DA-15-045)

National Institute on Drug Abuse

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in PAR-15-070 "Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)" - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-DA-15-045.html#sthash.2gfwhbVJ.dpuf

-----------

Notice of the National Institute on Drug Abuse (NIDA) Participation in PAR-15-071 "Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)" (NOT-DA-15-046)


National Institute on Drug Abuse

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in PAR-15-071 "Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)". - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-DA-15-046.html#sthash.My8Fw0RD.dpuf

-------

NIDA International Program Announcements R01: PA-15-142;R21: PA-15-143; R03: PA-15-141

 

NIDA has reissued its Program Announcements (PAs) soliciting collaborative research proposals between investigators from domestic U.S. institutions and researchers in other countries. The PAs—International Research Collaboration on Drug Abuse and Addiction Research—will be in effect until May 8, 2018.

Researchers may choose one of three grant programs in response to these broad calls for innovative research proposals: R01, R21, or R03.

Applications are encouraged in all areas of NIDA-supported science, including basic laboratory studies, clinical studies, epidemiological studies, community-based studies, and services research. Research priority areas include:

  • Linkages between HIV/AIDS and drug abuse
  • Marijuana
  • Amphetamine-type stimulants abuse
  • Synthetic and other designer drug abuse
  • Inhalant abuse
  • Smoking during pregnancy
  • Drugged driving
  • Projects that address NIDA's Divisional research priorities and crosscutting research issues.

-------------------

New BD2K Funding Opportunity, Supplements to Support Interoperability of NIH Funded Biomedical Data Repositories (Admin Supp)  PA-15-144. http://grants.nih.gov/grants/guide/pa-files/PA-15-144.html  

Application Receipt Date(s): April 20, 2015 

Program/Scientific Contact: 

Valentina Di Francesco
National Human Genome Research Institute (NHGRI)
Telephone: 301-496-7531|
Email:  
vdifrancesco@mail.nih.gov 

Background:

NIH is accepting administrative supplement requests to support projects that will establish or improve interoperability among NIH funded biomedical data repositories. Improved interoperability is expected to lead to increased efficiency of repositories' operations and cost reductions, which are significant factors of the NIH's long-term sustainability plans for the biomedical data repositories.  

Each supplement request should be associated to a collaborative project consisting of a biomedical data repository supported by an active NIH-funded parent grant, and one or more collaborating sites that together implement the interoperability goals of this FOA. The collaborating sites may be other biomedical data repositories, or may provide computational tools and data standards, or perform other activities that facilitate interoperability among data repositories. Supplement requests will only be accepted from active NIH-funded parent grants that primarily support biomedical data repositories with an overall annual budget above $500,000 in direct costs.

 

-----------

 

Big Data to Knowledge (BD2K) Advancing Biomedical Science Using Crowdsourcing and Interactive Digital Media (UH2)  RFA-CA-15-006

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-006.html

The NIH Big Data to Knowledge (BD2K) is pleased to announce the release of a new RFA, "Big Data to Knowledge (BD2K) Advancing Biomedical Science Using Crowdsourcing and Interactive Digital Media (UH2)". This RFA seeks to support the development of new or significantly adapted interactive digital media that engages the public, experts or non-experts, in performing some aspect of biomedical research via crowdsourcing. To be responsive to this FOA, each application is expected to pose a challenging biomedical research problem and propose the development of engaging interactive digital media that incorporates crowdsourcing as a fundamental component of how the problem is solved.  

BD2K was established to address the opportunities and challenges presented by the dawning era of big data in biomedical research.  BD2K is a trans-NIH initiative that supports a variety of related efforts designed to enhance the utility of biomedical big data with the goals of cultivating the digital research enterprise within biomedicine, facilitating discovery, and to maximizing community engagement.  For more information about BD2K please see http://bd2k.nih.gov/index.html.

 

Please share this information with your colleagues.

Letters of Intent Date: May 3, 2015

Receipt Date: June 3, 2015

Program Contact: David J. Miller, Ph.D.

Email: BD2K_targeted@mail.nih.gov  

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov     301-435-1309